Concepts (111)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Blood Group Antigens | 1 | 2021 | 202 | 0.76 | Why? |
| Antibodies, Anticardiolipin | 1 | 2017 | 208 | 0.61 | Why? |
| Antibodies, Antinuclear | 1 | 2017 | 234 | 0.59 | Why? |
| Lupus Coagulation Inhibitor | 1 | 2017 | 262 | 0.55 | Why? |
| Purpura, Thrombocytopenic, Idiopathic | 2 | 2019 | 645 | 0.48 | Why? |
| Hematologic Neoplasms | 4 | 2021 | 2105 | 0.33 | Why? |
| Thrombophilia | 1 | 2018 | 1935 | 0.30 | Why? |
| Turkey | 6 | 2021 | 3937 | 0.28 | Why? |
| Hematopoietic Stem Cell Transplantation | 4 | 2020 | 2426 | 0.23 | Why? |
| Respiration, Artificial | 5 | 2021 | 22116 | 0.22 | Why? |
| Lymphoma, T-Cell, Peripheral | 1 | 2019 | 12 | 0.20 | Why? |
| Hepatitis B | 2 | 2019 | 888 | 0.20 | Why? |
| Aminopterin | 1 | 2019 | 20 | 0.20 | Why? |
| Lymphoma, B-Cell, Marginal Zone | 1 | 2019 | 44 | 0.20 | Why? |
| Plasmapheresis | 2 | 2020 | 437 | 0.20 | Why? |
| Venous Thromboembolism | 1 | 2018 | 4273 | 0.20 | Why? |
| Hydrazines | 1 | 2019 | 68 | 0.19 | Why? |
| Antimetabolites, Antineoplastic | 1 | 2019 | 99 | 0.19 | Why? |
| Benzoates | 1 | 2019 | 102 | 0.19 | Why? |
| Arabinonucleosides | 1 | 2017 | 4 | 0.18 | Why? |
| Extracorporeal Circulation | 1 | 2020 | 130 | 0.18 | Why? |
| Adenine Nucleotides | 1 | 2017 | 43 | 0.18 | Why? |
| Regeneration | 1 | 2021 | 429 | 0.18 | Why? |
| Cytarabine | 1 | 2017 | 64 | 0.17 | Why? |
| Imatinib Mesylate | 1 | 2020 | 327 | 0.17 | Why? |
| Critical Care | 1 | 2021 | 14081 | 0.17 | Why? |
| Brucellosis | 1 | 2017 | 49 | 0.17 | Why? |
| Splenectomy | 1 | 2017 | 85 | 0.16 | Why? |
| Hepatitis C Antibodies | 1 | 2017 | 120 | 0.16 | Why? |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2020 | 314 | 0.16 | Why? |
| Hepatitis B Antibodies | 1 | 2017 | 142 | 0.16 | Why? |
| Hepatitis B Surface Antigens | 1 | 2017 | 305 | 0.15 | Why? |
| Salvage Therapy | 1 | 2017 | 417 | 0.14 | Why? |
| Febrile Neutropenia | 1 | 2017 | 179 | 0.14 | Why? |
| Hodgkin Disease | 1 | 2017 | 204 | 0.14 | Why? |
| Length of Stay | 3 | 2021 | 11042 | 0.14 | Why? |
| Helicobacter Infections | 1 | 2017 | 216 | 0.14 | Why? |
| Helicobacter pylori | 1 | 2017 | 262 | 0.13 | Why? |
| DNA | 1 | 2017 | 778 | 0.11 | Why? |
| Hospitalization | 2 | 2021 | 54280 | 0.11 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 1573 | 0.11 | Why? |
| Leukemia, Myeloid, Acute | 1 | 2017 | 676 | 0.11 | Why? |
| Neoplasm Recurrence, Local | 1 | 2017 | 1063 | 0.10 | Why? |
| Mesenchymal Stem Cell Transplantation | 1 | 2021 | 1322 | 0.10 | Why? |
| Risk Management | 1 | 2017 | 1044 | 0.10 | Why? |
| Pyrazoles | 1 | 2019 | 1791 | 0.09 | Why? |
| Retrospective Studies | 11 | 2021 | 105322 | 0.09 | Why? |
| Hepatitis C | 1 | 2017 | 1514 | 0.07 | Why? |
| Adolescent | 7 | 2021 | 86841 | 0.07 | Why? |
| Guideline Adherence | 1 | 2018 | 2309 | 0.07 | Why? |
| Young Adult | 7 | 2021 | 93724 | 0.07 | Why? |
| Aged, 80 and over | 6 | 2021 | 88759 | 0.07 | Why? |
| Sex Factors | 1 | 2021 | 11014 | 0.07 | Why? |
| Transplant Recipients | 1 | 2020 | 4982 | 0.07 | Why? |
| Venous Thrombosis | 1 | 2018 | 2739 | 0.06 | Why? |
| Aged | 10 | 2021 | 215776 | 0.06 | Why? |
| Middle Aged | 11 | 2021 | 270681 | 0.06 | Why? |
| Adult | 10 | 2021 | 244371 | 0.05 | Why? |
| Male | 13 | 2021 | 367725 | 0.05 | Why? |
| Intensive Care Units | 3 | 2021 | 29594 | 0.05 | Why? |
| Age Factors | 1 | 2021 | 21039 | 0.05 | Why? |
| Immunization, Passive | 3 | 2020 | 10067 | 0.05 | Why? |
| Female | 12 | 2021 | 380317 | 0.05 | Why? |
| Postoperative Complications | 1 | 2018 | 5861 | 0.05 | Why? |
| Humans | 20 | 2021 | 930598 | 0.05 | Why? |
| Immunoglobulin M | 1 | 2017 | 9091 | 0.05 | Why? |
| Thromboplastin | 1 | 2021 | 275 | 0.05 | Why? |
| Vidarabine | 1 | 2017 | 59 | 0.04 | Why? |
| Anticoagulants | 1 | 2018 | 9563 | 0.04 | Why? |
| Severity of Illness Index | 2 | 2021 | 48226 | 0.04 | Why? |
| Granulocyte Colony-Stimulating Factor | 1 | 2017 | 264 | 0.04 | Why? |
| Risk Factors | 3 | 2021 | 71621 | 0.04 | Why? |
| Transplantation, Homologous | 1 | 2018 | 757 | 0.04 | Why? |
| Anti-Bacterial Agents | 1 | 2017 | 10083 | 0.04 | Why? |
| Practice Guidelines as Topic | 1 | 2018 | 15421 | 0.03 | Why? |
| Drug Resistance, Neoplasm | 1 | 2017 | 447 | 0.03 | Why? |
| Donor Selection | 1 | 2020 | 804 | 0.03 | Why? |
| Plasma Exchange | 1 | 2020 | 763 | 0.03 | Why? |
| Immunoglobulin G | 1 | 2017 | 21571 | 0.03 | Why? |
| Disseminated Intravascular Coagulation | 1 | 2021 | 994 | 0.03 | Why? |
| Neoplasms | 1 | 2021 | 17251 | 0.03 | Why? |
| Lung | 1 | 2021 | 31049 | 0.03 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.03 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.03 | Why? |
| HIV Infections | 1 | 2017 | 11620 | 0.03 | Why? |
| Combined Modality Therapy | 1 | 2020 | 3395 | 0.03 | Why? |
| Protein Kinase Inhibitors | 1 | 2020 | 1585 | 0.03 | Why? |
| Plasma | 1 | 2020 | 1809 | 0.03 | Why? |
| Recurrence | 1 | 2019 | 3675 | 0.02 | Why? |
| Thromboembolism | 1 | 2021 | 2101 | 0.02 | Why? |
| Pandemics | 3 | 2020 | 389249 | 0.02 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.02 | Why? |
| Blood Donors | 1 | 2020 | 2956 | 0.02 | Why? |
| Chronic Disease | 1 | 2019 | 5139 | 0.02 | Why? |
| Antineoplastic Agents | 1 | 2020 | 3550 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2018 | 9537 | 0.02 | Why? |
| Immunosuppressive Agents | 1 | 2020 | 6331 | 0.01 | Why? |
| Peptidyl-Dipeptidase A | 1 | 2021 | 9659 | 0.01 | Why? |
| Fever | 1 | 2017 | 7795 | 0.01 | Why? |
| Cytokines | 1 | 2020 | 15010 | 0.01 | Why? |
| Critical Illness | 1 | 2020 | 17281 | 0.01 | Why? |
| Prospective Studies | 1 | 2021 | 43301 | 0.01 | Why? |
| Prognosis | 1 | 2019 | 32490 | 0.01 | Why? |
| Comorbidity | 1 | 2020 | 34796 | 0.01 | Why? |
| Cohort Studies | 1 | 2019 | 36005 | 0.01 | Why? |
| Child, Preschool | 1 | 2019 | 36283 | 0.01 | Why? |
| Time Factors | 1 | 2018 | 31397 | 0.01 | Why? |
| Risk Assessment | 1 | 2017 | 25439 | 0.01 | Why? |
| Treatment Outcome | 1 | 2018 | 51732 | 0.01 | Why? |
| Child | 1 | 2019 | 70012 | 0.01 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.01 | Why? |